SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) SEPTEMBER 17, 1998
--------------------------------
IDEC PHARMACEUTICALS CORPORATION
--------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Registrant's telephone number, including area code (619) 550-8500
------------------------------
NONE
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 5. Other Events.
On September 17, 1998, the Board of Directors of IDEC Pharmaceuticals
Corporation (the "Company") amended its Rights Agreement, dated as of July 22,
1997, between the Company and Chase Mellon Shareholder Services LLC (the "Rights
Agent") (the "Agreement"), to delete "continuing director" provisions throughout
the Agreement.
The Form of First Amendment to the Rights Agreement between the Company and
the Rights Agent, eliminating "continuing director" provisions, is attached
hereto as an exhibit and is incorporated herein by reference. The foregoing
description of the "continuing director" provisions is qualified in its entirety
by reference to such exhibit.
Item 7. Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IDEC PHARMACEUTICALS CORPORATION
DATE: December 31, 1998 By: /s/ Phillip M Schneider
-------------------------------
Name: Phillip M. Schneider
Title: Vice President and
Chief Financial Officer
EXHIBIT INDEX